Literature DB >> 2970970

Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3.

Z Y Feng1, J Louis, V Kindler, T Pedrazzini, J F Eliason, R Behin, P Vassalli.   

Abstract

Previous studies from our laboratory have shown that some in vitro maintained Leishmania major-specific L3T4+ T cells were capable of exacerbating cutaneous leishmaniasis after adoptive transfer to normal syngeneic mice. Results presented in this report show that these cells released substantial amounts of interleukin 3 (IL 3) and granulocyte-macrophage colony-stimulating factors after specific stimulation in vitro. In order to assess the involvement of such lymphokines in the exacerbation of cutaneous leishmaniasis by these L3T4+ T cells, the effect of the administration of important doses of IL 3 on the course of infection with L. major was investigated. The treatment of genetically susceptible BALB/c mice with IL 3 resulted in an enhancement of the size of lesions and favored the multiplication of parasites at anatomical sites distant from the primary lesion. Although IL 3 did not modify the development of lesions in genetically resistant CBA mice, this lymphokine promoted the growth of Leishmania in lymph node draining the lesion. Finally, the addition of IL 3 to macrophages parasitized in vitro enhanced the survival of intracellular Leishmania major.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970970     DOI: 10.1002/eji.1830180815

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Presence of a very small population of Thy-1+, L3T4+ cells producing large amounts of IL-3 in young athymic nude mice.

Authors:  M Kimoto; S de Kossodo; V Kindler; M Detraz; P Vassalli; S Izui
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

2.  T-lymphocytes in experimental Leishmania amazonensis infection: comparison between immunized and naive BALB/c mice.

Authors:  M Pompeu; A L Freitas; G A dosReis; M Barral-Netto
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

3.  Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.

Authors:  L P Kahl; R Lelchuk; C A Scott; J Beesley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Interleukin-3 protects mice from acute herpes simplex virus infection.

Authors:  W L Chan; H J Ziltener; F Y Liew
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

5.  Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice.

Authors:  K E Squires; M Kirsch; S C Silverstein; A Acosta; M J McElrath; H W Murray
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

6.  Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani.

Authors:  S E Cotterell; C R Engwerda; P M Kaye
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

7.  Infection of mice lacking interleukin-7 (IL-7) reveals an unexpected role for IL-7 in the development of the parasite Schistosoma mansoni.

Authors:  I Wolowczuk; S Nutten; O Roye; M Delacre; M Capron; R M Murray; F Trottein; C Auriault
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis.

Authors:  B Saha; A M D J Tonkal; S Croft; S Roy
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

10.  Interleukin-3 induces antimicrobial activity against Leishmania amazonensis and Trypanosoma cruzi and tumoricidal activity in human peripheral blood-derived macrophages.

Authors:  J L Ho; S G Reed; J Sobel; S Arruda; S H He; E A Wick; K H Grabstein
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.